Compounds > epirubicin
Page last updated: 2024-08-23

epirubicin and amifostine anhydrous

epirubicin has been researched along with amifostine anhydrous in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Czejka, M; Dempe, K; Kletzl, H; Pernkopf, I; Schüller, J; Tesch, G1
Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E1
Beijnen, JH; Hoekman, K; Huijskes, RV; Nannan Panday, VR; Rosing, H; Van den Brande, J; Verheijen, RH; Vermorken, JB1
Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E1

Reviews

1 review(s) available for epirubicin and amifostine anhydrous

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for epirubicin and amifostine anhydrous

ArticleYear
[Binding of epirubicin to human plasma protein and erythrocytes: interaction with the cytoprotective amifostine].
    Die Pharmazie, 1996, Volume: 51, Issue:11

    Topics: Amifostine; Antibiotics, Antineoplastic; Blood Proteins; Cysteine; Doxorubicin; Epirubicin; Erythrocytes; Glutathione; Humans; Protein Binding

1996
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine

2001
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
    American journal of clinical oncology, 2001, Volume: 24, Issue:4

    Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Radiation-Protective Agents; Radiation-Sensitizing Agents

2001
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Dose Fractionation, Radiation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Mastectomy, Modified Radical; Middle Aged; Nausea; Radiation Pneumonitis; Radiation-Protective Agents; Radiobiology; Radiodermatitis; Radiotherapy, Adjuvant; Survival Analysis; Vomiting

2002